Taken together, i.t. administration of IMSA101 improved CART trafficking into the tumor, induced intra-tumoral CART activation, and enhanced anti-tumor efficacy and overall survival in syngeneic mouse models, which was, to a significant extent, facilitated through STING agonist-mediated IL-18 induction. This evidence concerns the gene CARTPT and neoplasm.